Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions
Biomolecules · 28.04.2025 · 15 (5) · 633
DOI: 10.3390/biom15050633 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 28.04.2025. Verfasst von Shumin Zhan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzho…. Hauptthemen laut MEDLINE: Biomarkers, Obesity, Metabolic Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Research Fund of National Health Commission & Zhejiang major Health Science and Technology, Leading Geese plan in Zhejiang Province.
Abstract (Originalsprache)
Obesity-related metabolic diseases include conditions linked to obesity, such as type 2 diabetes, hypertension, steatotic liver disease, and polycystic ovary syndrome. These disorders are primarily caused by insulin resistance, chronic inflammation, and excessive fat accumulation. They represent significant health challenges and often remain asymptomatic during their early stages. Traditional diagnostic tools, including blood glucose, lipid levels, blood pressure, and uric acid measurements, provide valuable insights but fall short of fully capturing the complexity of metabolic dysfunction. Consequently, there is a growing need for noninvasive, easily accessible biomarkers, especially those found in urine, to enable more accurate, sensitive, and patient-friendly diagnostic methods. Urine, with its diverse range of metabolites that reflect the body’s metabolic changes, is an ideal sample for early detection. Recent advancements in urine metabolomics and proteomics have highlighted the potential of urinary biomarkers for diagnosing obesity-related metabolic diseases. Despite challenges such as the need for standardized detection techniques and clinical validation, the integration of artificial intelligence and multi-omics approaches holds significant promise for enhancing diagnostic accuracy and advancing disease management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310051, China.
ORCID-Profile: Xuelian Zhou, Junfen Fu
Förderung
- National Key Research and Development Program of China
- Research Fund of National Health Commission & Zhejiang major Health Science and Technology
- Leading Geese plan in Zhejiang Province
- Research Fund of National Health Commission & Zhejiang major Health Science and Technology
- Zhejiang province Multidisciplinary innovation team of traditional Chinese medicine for diabetes diagnosis and treatment
Zitieren
APA
Zhan, S., Zhou, X., & Fu, J. (2025). Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions. Biomolecules, 15(5), 633. https://doi.org/10.3390/biom15050633
Vancouver
Zhan S, Zhou X, Fu J. Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions. Biomolecules. 2025;15(5):633. doi:10.3390/biom15050633
BibTeX
@article{Zhan2025,
author = {Zhan, Shumin and Zhou, Xuelian and Fu, Junfen},
title = {Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {5},
pages = {633},
doi = {10.3390/biom15050633}
}
EUVIMED